International AIDS Vaccine Initiative (IAVI)

iavi.org

The International AIDS Vaccine Initiative (IAVI) is a nonprofit scientific organization whose mission is to develop vaccines and other biomedical innovations that prevent HIV infection. Since its founding in 1996, IAVI has provided scientific, research and development, and policy leadership to address the needs of communities and key populations at risk for HIV infection around the world. IAVI works with more than 100 academic, industry, government, civil society, clinical, and community partners in more than 25 countries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

VERSANTIS TO PRESENT POSITIVE PHASE 1B DATA AT AASLD FOR VS-01 IN PATIENTS WITH DECOMPENSATED CIRRHOSIS

Versantis | November 15, 2021

news image

Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, announced that positive Phase 1b clinical data from a study of its lead investigational, orphan-designated product, VS-01, in 12 hospitalized patients with decompensated liver cirrhosis will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data show that VS-01 was safe and well tolerated in these patients, and demonstrated promi...

Read More

XYLYX BIO LAUNCHES SPECIALIZED CONTRACT R&D SERVICES THAT SUPPORT IMPROVED ASSESSMENT OF ANTIFIBROTIC DRUG CANDIDATE EFFICACY

Xylyx Bio | September 30, 2020

news image

Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Approximately 40% of development costs are associated with preclinical studies, yet 80% of drug candidates fail before reaching Phase I trials, largely due to lack of translatability of efficacy data to hum...

Read More

ENSYSCE, A CALIFORNIA BASED BIOTECH COMPANY WITH A MISSION TO SOLVE THE OPIOID CRISIS, EXPLORING A TREATMENT FOR COVID-19

TheDailyTimes | April 15, 2020

news image

Ensysce Biosciences announced that it is exploring the opportunity to initiate a clinical trial of oral Nafamostat, an ingredient from its opioid overdose protection platform, as a treatment for COVID-19. The goal is to evaluate if nafamostat mesylate (Nafamostat), a synthetic protease inhibitor will be effective in preventing or reducing the lethal outcome of COVID-19 infection. Currently, there are no approved drugs to manage infection with SARS-CoV-2 and nafamostat has shown promise in severa...

Read More

Industrial Impact

TRANSPERFECT LIFE SCIENCES AND INNOVADERM RESEARCH EXPAND TRIAL INTERACTIVE PARTNERSHIP

TransPerfect Life Sciences | February 16, 2022

news image

TransPerfect Life Sciences, a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, today announced that Innovaderm will scale their implementation of Trial Interactive to further enable and optimize remote clinical operations. Innovaderm, a North America-based contract research organization (CRO) that specializes in clinical studies for dermatology, leveraged Trial Interactive remote monitoring ...

Read More
news image

MedTech

VERSANTIS TO PRESENT POSITIVE PHASE 1B DATA AT AASLD FOR VS-01 IN PATIENTS WITH DECOMPENSATED CIRRHOSIS

Versantis | November 15, 2021

Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, announced that positive Phase 1b clinical data from a study of its lead investigational, orphan-designated product, VS-01, in 12 hospitalized patients with decompensated liver cirrhosis will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data show that VS-01 was safe and well tolerated in these patients, and demonstrated promi...

Read More
news image

XYLYX BIO LAUNCHES SPECIALIZED CONTRACT R&D SERVICES THAT SUPPORT IMPROVED ASSESSMENT OF ANTIFIBROTIC DRUG CANDIDATE EFFICACY

Xylyx Bio | September 30, 2020

Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Approximately 40% of development costs are associated with preclinical studies, yet 80% of drug candidates fail before reaching Phase I trials, largely due to lack of translatability of efficacy data to hum...

Read More
news image

ENSYSCE, A CALIFORNIA BASED BIOTECH COMPANY WITH A MISSION TO SOLVE THE OPIOID CRISIS, EXPLORING A TREATMENT FOR COVID-19

TheDailyTimes | April 15, 2020

Ensysce Biosciences announced that it is exploring the opportunity to initiate a clinical trial of oral Nafamostat, an ingredient from its opioid overdose protection platform, as a treatment for COVID-19. The goal is to evaluate if nafamostat mesylate (Nafamostat), a synthetic protease inhibitor will be effective in preventing or reducing the lethal outcome of COVID-19 infection. Currently, there are no approved drugs to manage infection with SARS-CoV-2 and nafamostat has shown promise in severa...

Read More
news image

Industrial Impact

TRANSPERFECT LIFE SCIENCES AND INNOVADERM RESEARCH EXPAND TRIAL INTERACTIVE PARTNERSHIP

TransPerfect Life Sciences | February 16, 2022

TransPerfect Life Sciences, a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, today announced that Innovaderm will scale their implementation of Trial Interactive to further enable and optimize remote clinical operations. Innovaderm, a North America-based contract research organization (CRO) that specializes in clinical studies for dermatology, leveraged Trial Interactive remote monitoring ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us